We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+83.78%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$212M
Cap. Flow
-$46.3M
Cap. Flow %
-4.15%
Top 10 Hldgs %
42.31%
Holding
75
New
24
Increased
13
Reduced
13
Closed
16

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$25.4M
2
VSTM icon
Verastem
VSTM
+$22.7M
3
PCVX icon
Vaxcyte
PCVX
+$20.7M
4
LBRX
LB Pharmaceuticals
LBRX
+$17.9M
5
ARVN icon
Arvinas
ARVN
+$17.3M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$30M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$26.5M
3
UTHR icon
United Therapeutics
UTHR
+$24.4M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
5
KROS icon
Keros Therapeutics
KROS
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 90.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
26
Amylyx Pharmaceuticals
AMLX
$2.04B
$19.7M 1.77%
+1,450,000
New +$13.6M
LBRX
27
LB Pharmaceuticals
LBRX
$1B
$17.8M 1.6%
+1,130,000
New +$17.9M
QURE icon
28
uniQure
QURE
$2.64B
$17.5M 1.57%
+300,000
New +$5.45M
KYMR icon
29
Kymera Therapeutics
KYMR
$9.13B
$14.2M 1.27%
+250,000
New +$11.3M
BIIB icon
30
Biogen
BIIB
$29.8B
$14M 1.26%
100,000
-100,000
-50% -$13.5M
ACLX
31
DELISTED
Arcellx
ACLX
$13.5M 1.21%
+165,000
New +$11.9M
KROS icon
32
Keros Therapeutics
KROS
$204M
$13.4M 1.21%
850,000
-1,150,000
-58% -$17M
CNTA
33
DELISTED
Centessa Pharmaceuticals
CNTA
$12.7M 1.14%
+525,000
New +$9.33M
IDYA icon
34
CALL
IDEAYA Biosciences
IDYA
$3.49B
$12.2M 1.1%
+450,000
New +$10.9M
JANX icon
35
CALL
Janux Therapeutics
JANX
$956M
$12.2M 1.1%
500,000
– –
LRMR icon
36
CALL
Larimar Therapeutics
LRMR
$398M
$8.07M 0.72%
2,500,000
– –
TNGX icon
37
Tango Therapeutics
TNGX
$4.37B
$7.98M 0.72%
+950,000
New +$6.43M
DNTH icon
38
Dianthus Therapeutics
DNTH
$5.72B
$7.87M 0.71%
+200,000
New +$5.11M
COGT icon
39
Cogent Biosciences
COGT
$6.91B
$7.18M 0.64%
+500,000
New +$5.92M
CMPX icon
40
Compass Therapeutics
CMPX
$384M
$7.17M 0.64%
+2,050,000
New +$6.48M
CBIO
41
Crescent Biopharma
CBIO
$636M
$7.13M 0.64%
600,000
+46,314
+8% +$614K
ELVN icon
42
Enliven Therapeutics
ELVN
$3.84B
$6.96M 0.62%
340,000
-10,000
-3% -$202K
IMRX icon
43
Immuneering
IMRX
$281M
$6.65M 0.6%
+950,000
New +$4.93M
PRAX icon
44
Praxis Precision Medicines
PRAX
$9.01B
$6.63M 0.59%
125,000
-100,000
-44% -$4.85M
SRRK icon
45
Scholar Rock
SRRK
$5.92B
$6.52M 0.58%
+175,000
New +$6.12M
JBIO
46
Jade Biosciences
JBIO
$1.25B
$5.39M 0.48%
625,000
– –
EPRX
47
Eupraxia Pharmaceuticals
EPRX
$397M
$5.31M 0.48%
+900,000
New +$4.9M
IMVT icon
48
Immunovant
IMVT
$8.26B
$4.43M 0.4%
275,000
– –
PHVS icon
49
Pharvaris
PHVS
$2.38B
$3.74M 0.34%
+150,000
New +$3.33M
ATXS
50
DELISTED
Astria Therapeutics
ATXS
$3.64M 0.33%
500,000
-200,000
-29% -$1.35M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2025 Portfolio in Review

As of Q3 2025, Logos Global Management held 75 positions worth $1.12B, up 23% from $904M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Logos Global Management withdrew a net $46.3M in Q3 2025, closing 16 positions and reducing 13 holdings. Its most notable exit was United Therapeutics, an estimated $24.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 83% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Abivax worth $35.2M.

  • Logos Global Management's largest Q3 2025 buy was Abivax: 415,000 shares worth $35.2M.
  • Logos Global Management added most to Verastem in Q3 2025, an estimated $22.7M increase.
  • Logos Global Management's biggest Q3 2025 reduction was Jazz Pharmaceuticals, cutting an estimated $30M.
  • Logos Global Management fully exited United Therapeutics in Q3 2025, selling an estimated $24.4M.
  • Logos Global Management's ten largest holdings make up 42% of its $1.12B portfolio in Q3 2025.
  • Logos Global Management opened 24 new positions and closed 16 in Q3 2025.
  • Logos Global Management's portfolio value rose 23% quarter-over-quarter to $1.12B.

Based on Logos Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.